MANAGEMENT OF INFLAMMATORY NEUROPATHIES
Open Access
- 1 June 2003
- journal article
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 74 (90002) , 9ii-14
Abstract
GBS is a clinically defined syndrome with several underlying pathologies. It affects 1–4 per 100 000 per year, men slightly more often than women. Diagnostic criteria1 include progressive weakness of two or more limbs reaching a maximum within four weeks, reduced or absent tendon reflexes in the weak limbs, and exclusion of alternative causes (box 1).2 Some cases may be so mild that medical attention is never sought. Most cases are caused by acute inflammatory demyelinating polyradiculoneuropathy (AIDP), but some are caused by acute motor axonal neuropathy (AMAN) or acute motor and sensory axonal neuropathy (AMSAN).3 Primary axonal GBS is thought to be caused by an autoimmune attack on axonal antigens, and is common in Asia, but is responsible for less than 5% of GBS cases in Europe and North America. Reflexes are sometimes preserved in AMAN. Rarer variants of GBS are the pharyngo-cervico-brachial pattern, acute oropharyngeal palsy (not to be confused with diphtheria), involvement of the lower but not upper limbs, and a pure motor and a pure sensory form. Acute pandysautonomia and acute sensory neuronopathy may also be related.Keywords
This publication has 4 references indexed in Scilit:
- Peripheral neuropathies and anti-glycolipid antibodiesBrain, 2002
- The spectrum of antecedent infections in Guillain-Barré syndromeNeurology, 1998
- Guillain-Barré syndrome in northern China: The spectrum of neuropathological changes in clinically defined casesBrain, 1995
- Assessment of current diagnostic criteria for Guillain-Barr syndromeAnnals of Neurology, 1990